Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
0.1600
-0.0056 (-3.38%)
At close: Jun 9, 2026, 4:00 PM EDT
0.1655
+0.0055 (3.44%)
Pre-market: Jun 10, 2026, 5:59 AM EDT
Gossamer Bio Revenue
Gossamer Bio had revenue of $16.96M in the quarter ending March 31, 2026, with 71.45% growth. This brings the company's revenue in the last twelve months to $55.54M, down -55.42% year-over-year. In the year 2025, Gossamer Bio had annual revenue of $48.47M, down -57.74%.
Revenue (ttm)
$55.54M
Revenue Growth
-55.42%
P/S Ratio
0.68
Revenue / Employee
$342,821
Employees
162
Market Cap
37.55M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 48.47M | -66.23M | -57.74% |
| Dec 31, 2024 | 114.70M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Plus Therapeutics | 5.18M |
| Nutriband | 2.04M |
| RenovoRx | 1.49M |
| Hyperion DeFi | 1.04M |
| aTyr Pharma | 190.00K |
GOSS News
- 22 hours ago - Gossamer Bio Proxy statement: Proxy filing - Filings
- 6 days ago - Gossamer Bio announces early tender results, early settlement of solicitation - TheFly
- 6 days ago - Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes - Business Wire
- 7 days ago - Gossamer Bio announces extension of early tender date for exchange offer - TheFly
- 7 days ago - Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes - Business Wire
- 12 days ago - Investors Sue Gossamer Bio (GOSS) Over Inflated High Blood Pressure Study Claims - TipRanks
- 20 days ago - Goldman Sachs suspends rating on Gossamer Bio - TheFly
- 22 days ago - Gossamer Bio price target lowered to 28c from 30c at Barclays - TheFly